FDA Grants Fast Track Designation to Zotiraciclib for Treatment of Recurrent High-Grade Glioma with IDH1/2 Mutations December 2, 2025
Fast Track Designation for AVZO-103 for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin December 2, 2025
FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced CSCC December 2, 2025
Swiss medical authority approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) combination as 1L maintenance therapy for ES-SCLC December 2, 2025
